Latest Humanized antibody Stories
INCLINE VILLAGE, Nev., July 5, 2011 /PRNewswire/ -- PDL BioPharma, Inc.
ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.
INCLINE VILLAGE, Nev., June 16, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the June 15, 2011, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of June 8, 2011, the record date.
PLANTATION, Fla. and MONTREAL, June 2, 2011 /PRNewswire/ -- Goodwin Biotechnology, Inc.
INCLINE VILLAGE, Nev., May 3, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P.
INCLINE VILLAGE, Nev., April 18, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will hold its annual meeting of stockholders on Wednesday, June 22, 2011 at 10:00 a.m. Pacific Time for all stockholders of record on April 25, 2011.
BURLINGAME, Calif., March 11, 2011 /PRNewswire/ -- Apexigen, Inc., an emerging biopharmaceutical company focusing on the development of monoclonal antibody therapeutics, announced today that its partner, Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) of China to evaluate APX003 (also known as BD0801) as a potential cancer therapy.
- Having no light.
- Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.